Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Associations between calprotectin, tumour necrosis factor inhibitor trough serum levels and power Doppler ultrasound synovitis

From: Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity

  Unadjusted β coefficient Fully adjusted β coefficient
  OR (95 % CI) p Value OR (95 % CI) p Value
Calprotectin, μg/ml 3.22 (1.95–5.33) <0.0001 4.63 (2.31–9.26) <0.0001
TNFi trough serum levels, μg/ml 0.77 (0.65–0.91) 0.002 0.67 (0.52–0.85) 0.001
Age, years 1.03 (0.99–1.06) 0.164   
Disease duration, years 1.05 (1.00–1.10) 0.067 1.10 (1.02–1.18) 0.016
ESR, mm/h 1.13 (1.05–1.22) 0.001   
Female sex 2.92 (1.18–7.20) 0.020   
Combined therapy, yes or no 1.64 (0.72–3.76) 0.245   
Disease activity according to DAS28-ESR   0.001   
Remission (<2.6) 1    
Low disease activity (2.6–3.2) 7.35 (2.23–24.21)    
Reduced dose, yes or no 0.63 (0.27–1.44) 0.271   
Diagnostic   0.002   
 RA 1    
 PsA 0.26 (0.11–0.62)    
Steroids, yes or no 2.67 (0.83–8.55) 0.099 18.12 (2.73–120.16) 0.003
Monotherapy, yes or no 0.59 (0.26–1.34) 0.206   
Constant    0.02 (0.003–0.16) <0.0001
  1. Abbreviations: DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumour necrosis factor inhibitors